Bavarian Nordic A/S Sponsored ADR (BVNRY)
Summary
BVNRY Chart
People also search for
Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript
Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript
Bavarian Nordic A/S (BVNRY) Q4 2025 Earnings Call Transcript
Bavarian Nordic A/S (BVNRY) Q4 2025 Earnings Call Transcript
Bavarian Nordic A/S (BVNRY) Q3 2025 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNRY) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Paul Chaplin - CEO & President Henrik Juuel - CFO & Executive VP Conference Call Participants Romy O'Connor - Van Lanschot Kempen NV Thomas Bowers - SEB, Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Bavarian Nordic Third Quarterly Report for the 9-month period ended 30th of September 2025 Conference Call on Webcast.
Bavarian Nordic A/S Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Lyn Dippel Curio Wealth LLC | 1 | $10 | $9.05 | -$0.95 | -9.5% |
Bavarian Nordic A/S Sponsored ADR (BVNRY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bavarian Nordic A/S Sponsored ADR ever had a stock split?
Bavarian Nordic A/S Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Paul John Chaplin CEO | OTC PINK Exchange | 071771109 CUSIP |
| DK Country | 1,861 Employees | 6 Apr 2020 Last Dividend | 30 Mar 2020 Last Split | - IPO Date |
Overview
Bavarian Nordic A/S is a leading biotechnology company focused on developing, manufacturing, and commercializing life-saving vaccines for a global customer base. Founded in 1992 and headquartered in Hellerup, Denmark, the company has made significant strides in the vaccine industry, offering solutions for some of the world's most serious infectious diseases. Bavarian Nordic operates across various countries including the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and more, reflecting its wide-reaching influence and commitment to public health on an international scale. Through strategic license and collaboration agreements with entities like AdaptVac, the National Cancer Institute, and Public Health Service, Bavarian Nordic continues to advance its research and development efforts, aiming to deliver innovative vaccine solutions.
Products and Services
- IMVAMUNE, IMVANEX, and JYNNEOS:
- Rabipur/RabAvert:
- Encepur:
- MVABEA:
- MVA-BN for smallpox:
- MVA-BN RSV (Phase III clinical trials):
- ABNCoV2 (Completed Phase III clinical trial):
These are non-replicating vaccines used primarily for the prevention of smallpox and monkeypox. Through advanced technology, these vaccines offer safety and efficacy, providing crucial protection against these dangerous diseases.
A rabies vaccine for human use, known for its reliability and effectiveness. This vaccine plays a key role in preventing rabies, a life-threatening disease transmitted through the bites of infected animals.
This vaccine is designed to combat tick-borne encephalitis (TBE), a viral infectious disease involving the central nervous system. Encepur is a testament to Bavarian Nordic's commitment to addressing less common but serious infections.
Developed for the prevention of Ebola, a severe, often fatal illness in humans. The MVABEA vaccine represents a milestone in the fight against the Ebola virus, emphasizing the company's role in tackling emerging global health threats.
Currently in development, this treatment is another layer of Bavarian Nordic's defense against smallpox, aimed at providing enhanced protection and treatment options for this eradicated yet still concerning viral disease.
This vaccine candidate is in advanced testing for the treatment of the respiratory syncytial virus (RSV), a major cause of respiratory illness in infants and elderly individuals. MVA-BN RSV highlights Bavarian Nordic's ongoing efforts to expand its vaccine portfolio into respiratory diseases.
ABNCoV2 is a next-generation vaccine for the treatment of SARS-CoV-2, the virus responsible for COVID-19. Having completed Phase III clinical trial, this vaccine underscores Bavarian Nordic's commitment to responding rapidly to global pandemics and improving vaccine technology.
